Asia Pacific Acute Myeloid Leukemia Diagnostics Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2024 –2030 |
 Tamanho do mercado (ano base ) | |
 Tamanho do mercado ( Ano de previsão) | USD 1,206.57 |
 CAGR |
% |
| Principais participantes do mercado |
>Mercado de diagnóstico de leucemia mieloide aguda Ásia-Pacífico, por tipo de produto (instrumentos e consumíveis e acessórios), tipo de teste (teste de imagem, exame de sangue, testes de medula óssea, teste de biomarcadores, imunofenotipagem, testes genéticos e outros ), tipo de cancro (mieloblástico ( M0), mieloblástico (M1), mieloblástico (M2), promielocítico (M3), mielomonocítico (M4), monocítico (M5), eritroleucemia (M6) e megacariocítico (M7)), grupo etário ( abaixo dos 21, 21-29, 30-65 e 65 anos e mais), sexo (masculino e feminino), utilizador final (hospital, laboratórios associados, laboratórios de diagnóstico independentes, centros de diagnóstico por imagem, institutos de investigação do cancro e outros), canal de distribuição (concurso direto e vendas a retalho) Tendências e previsões da indústria para 2030.
Análise e insights do mercado de diagnóstico de leucemia mieloide aguda da Ásia-Pacífico
Devido ao aumento das despesas com cuidados de saúde, há um impulso no crescimento do mercado, e isto pode resultar em melhores ofertas de oportunidades de I&D. Além disso, os crescentes laboratórios de investigação clínica e de diagnóstico para o diagnóstico do cancro estão a permitir a expansão do mercado.
O mercado de diagnóstico de leucemia mieloide aguda da Ásia-Pacífico deverá crescer no período de previsão de 2023 a 2030. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 11,1% no período de previsão de 2023 a 2030 e prevê-se que atinja os 1.206,57 milhões de dólares até 2030.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2023 a 2030 |
|
Ano base |
2022 |
|
Ano histórico |
2021 (personalizável para 2020-2016) |
|
Unidades Quantitativas |
Receita em milhões de dólares |
|
Segmentos cobertos |
Por tipo de produto (instrumentos, consumíveis e acessórios), tipo de teste (exame de imagem, exame de sangue, exames de medula óssea, teste de biomarcadores, imunofenotipagem, testes genéticos e outros), tipo de cancro (mieloblástico (M0), mieloblástico (M1), mieloblástico (M2), promielocítica (M3), mielomonocítica (M4), monocítica (M5), eritroleucemia (M6) e megacariocítica (M7)), grupo etário (abaixo dos 21, 21-29, 30-65 e 65 e acima) , Género (Masculino e Feminino), Utilizador Final (Hospital, Laboratórios Associados, Laboratórios de Diagnóstico Independentes, Centros de Diagnóstico por Imagem, Institutos de Investigação do Cancro e Outros), Canal de Distribuição (Concurso Directo e Venda a Retalho). |
|
Países abrangidos |
China, Japão, Índia, Austrália, Coreia do Sul, Indonésia, Filipinas, Tailândia, Malásia, Vietname, Singapura e restante Ásia-Pacífico. |
|
Participantes do mercado abrangidos |
CANON MEDICAL SYSTEMS CORPORATION, Sysmex Corporation, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, Abbott, QIAGEN, Agilent Technologies, Inc, BIOMÉRIEUX e Exact Sciences Corporation, entre outros. |
Definição de mercado
A forma mais comum de cancro do sangue, a leucemia mieloide aguda (LMA), é também uma das formas pouco frequentes de leucemia. Esta forma de cancro invade o sangue, que depois se espalha para os órgãos e sistemas corporais próximos. Os especialistas devem diagnosticar manualmente as células cancerígenas e não cancerígenas, examinando as imagens das células ao microscópio e fornecendo etiquetas através de anotação.
O aumento das despesas com cuidados de saúde pode resultar em melhores oportunidades de I&D, o que também impulsiona o crescimento do negócio. A crescente infinidade de pesquisas clínicas e laboratórios de diagnóstico para o pré-teste do cancro está a permitir a expansão do mercado.
O crescente número de casos de cancro e a crescente consciencialização sobre a leucemia levaram ao aumento do crescimento do mercado.
O mercado de diagnóstico de leucemia mieloide aguda da Ásia-Pacífico está a crescer no ano previsto devido ao aumento dos participantes do mercado e à disponibilidade de instrumentos e consumíveis de imagem avançados. A par disto, os fabricantes estão empenhados em atividades de I&D para lançamento de produtos no mercado. O aumento da I&D e dos pré-testes estão a impulsionar ainda mais o crescimento do mercado. No entanto, espera-se que os regulamentos e normas rigorosas para a aprovação e comercialização de produtos para o diagnóstico de cancro e diagnóstico tardio atuem como um desafio ao crescimento do mercado.
Dinâmica do mercado de diagnóstico de leucemia mieloide aguda da Ásia-Pacífico
Esta secção trata da compreensão dos impulsionadores, restrições, oportunidades e desafios do mercado. Tudo isto é discutido em detalhe abaixo:
MOTORISTAS
- Crescente prevalência de cancro de leucemia
Todas as idades podem ser afetadas pela leucemia. A leucemia pode ser difícil de diagnosticar porque, apesar da sua vasta gama de sinais e sintomas, é inespecífica e pode estar associada a outras condições médicas mais generalizadas. A LMA é um dos quatro tipos comuns de leucemia em adultos. Ocorre com menos frequência. É um pouco mais comum entre homens do que mulheres, no entanto, o risco médio ao longo da vida de contrair LMA em ambos os sexos é de cerca de ½ de 1%, em média.
A LMA é o segundo tipo mais comum de leucemia diagnosticada em adultos e crianças, mas a maioria dos casos ocorre em adultos. Embora possa ser diagnosticada em qualquer idade, é pouco frequente antes dos 45 anos. A idade média de diagnóstico é de 68 anos.
Devido a vários factores de risco, a incidência da LMA tem vindo a aumentar, tornando-se um problema socioeconómico significativo. Espera-se que isto atue como um motor para o crescimento do mercado.
- Novos avanços tecnológicos no diagnóstico da leucemia
A forma mais comum de cancro do sangue, a LMA, é também uma das formas pouco frequentes de leucemia. Esta forma de cancro invade o sangue, que depois se espalha para os órgãos e sistemas corporais próximos. Os especialistas devem diagnosticar manualmente as células cancerígenas e não cancerígenas, examinando as imagens das células ao microscópio e fornecendo etiquetas através de anotação. No entanto, este exame microscópico da mão é demorado e pode fornecer um diagnóstico incorreto.
O risco de prescrição de medicamentos incorretos foi então reduzido com a utilização de software informatizado. A criação de um sistema de classificação automático e fiável tornou-se vital para travar os efeitos devastadores da doença leucémica. Múltiplas técnicas de segmentação constituíram a base dos algoritmos de classificação de leucemia existentes.
O desenvolvimento de vários novos métodos de diagnóstico aumentará o crescimento do mercado à medida que muitos produtos novos e avançados forem lançados. Assim, espera-se criar procura por produtos de diagnóstico de cancro leucémico agudo no mercado.
RESTRIÇÕES
- Regulamentação e normas rigorosas para aprovação e comercialização de produtos para diagnóstico de leucemia
As rigorosas regulamentações para a comercialização de qualquer produto no mercado estão a revelar-se um grande desafio para os fabricantes de produtos de diagnóstico de cancro que possuem regulamentos e um organismo diferenciado para os procedimentos regulamentares.
Os fabricantes devem primeiro verificar a aprovação da marca CE para a comercialização dos seus produtos no mercado. Espera-se que as rigorosas políticas regulamentares prejudiquem o crescimento e o desenvolvimento do mercado.
- Diagnóstico tardio e mau prognóstico de leucemia
O cancro é a principal causa de morte no mundo. No entanto, se forem identificados precocemente e receberem os cuidados adequados, alguns tipos de cancro podem ser curados. O processo de diagnóstico pode sofrer atrasos no diagnóstico do cancro. Quando os doentes ignoram ou não respondem a possíveis sinais cancerígenos, o diagnóstico é adiado. A principal causa da apresentação tardia é a falta de conhecimento público dos sinais iniciais do cancro, especialmente se tais sintomas forem pouco frequentes.
O diagnóstico tardio decorre muitas vezes destes fatores, que resultam num mau prognóstico. Assim, espera-se que estes restrinjam o crescimento do mercado.
OPORTUNIDADE/DESAFIOS
- Aumento das questões de custo, segurança e conveniência
A leucemia é um cancro fatal, e o processo de diagnóstico da leucemia também apresenta problemas de segurança. Não é rentável. Um dos distúrbios médicos mais dispendiosos de tratar é o cancro. Os doentes oncológicos podem ser hospitalizados e receber uma variedade de terapias, como cirurgia, radioterapia e terapia sistémica. Os prémios de seguro de saúde para doentes com cancro são agora mais caros do que no passado. Além disso, os custos de copagamento, franquia e cosseguro estão a aumentar.
Doravante, o atual processo de diagnóstico da leucemia apresenta questões de segurança, custo e conveniência, que deverão funcionar como um desafio ao crescimento do mercado.
Desenvolvimentos recentes
- Em novembro de 2022, a Canon Inc. adquiriu a Redlen Technologies Inc. (Redlen), uma das empresas líderes mundiais na criação de novas tecnologias relacionadas com o desenvolvimento e fabrico de módulos detetores semicondutores. A Canon Medical Systems Corporation (Canon Medical), uma empresa do grupo Canon Inc., desenvolveu o primeiro sistema de TC de contagem de fotões (PCCT) produzido internamente, incorporando as tecnologias avançadas da Redlen. Este sistema foi instalado no Centro Exploratório de Investigação Oncológica e Ensaios Clínicos do National Cancer Center (NCC) no Japão, onde é atualmente utilizado para conduzir investigação que explora as aplicações clínicas do PCCT.
- Em outubro de 2022, o presidente da Sysmex Corporation e o seu CEO: Hisashi Ietsugu anuncia a aprovação de um pedido de alteração parcial na aprovação de fabrico e comercialização no Japão do seu reagente de amplificação genética LYNOAMP CK19 comercializado como reagente de teste de metástase de linfonodo para o cancro da mama , cancro colorretal, cancro gástrico e cancro do pulmão de células não pequenas, expandindo a sua amplificação para o cancro do colo do útero e cancro do endométrio.
Âmbito do mercado de diagnóstico de leucemia mielóide aguda da Ásia-Pacífico
O mercado de diagnóstico de leucemia mieloide aguda da Ásia-Pacífico está segmentado em sete segmentos notáveis com base no tipo de produto, tipo de teste, tipo de cancro, faixa etária, sexo, utilizador final e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar os principais segmentos de crescimento nas indústrias e a fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para tomar decisões estratégicas para identificar as principais aplicações do mercado.
Tipo de produto
- Instrumentos
- Consumíveis e acessórios
Com base no tipo de produto, o mercado está segmentado em instrumentos e consumíveis e acessórios.
Tipo de teste
- Exame de sangue
- Teste de imagem
- Teste de Medula Óssea
- Teste Genético
- Teste de biomarcador
- Imunofenotipagem
- Outros
Com base no tipo de teste, o mercado está segmentado em análises ao sangue, exames de imagem, testes de medula óssea, testes genéticos, testes de biomarcadores, imunofenotipagem, entre outros.
Tipo de cancro
- Mieloblástico (M0)
- Mieloblástico (M1)
- Mieloblástico (M2)
- Promielocítico (M3)
- Mielomonocítico (M4)
- Monocítico (M5)
- Eritroleucemia (M6)
- Megacariocítico (M7)
Com base no tipo de cancro, o mercado está segmentado em mieloblástico (M0), mieloblástico (M1), mieloblástico (M2), promielocítico (M3), mielomonocítico (M4), monocítico (M5), eritroleucemia (M6) e megacariocítico (M7 ) .
Faixa etária
- Abaixo de 21
- 21-29
- 30-65
- 65 e acima
Com base na faixa etária, o mercado está segmentado em abaixo dos 21, 21-29, 30-65 e 65 anos e acima.
Género
- Macho
- Fêmea
Com base no género, o mercado está segmentado em masculino e feminino.
Utilizador final
- Hospital
- Laboratórios Associados
- Laboratórios de diagnóstico independentes
- Centros de diagnóstico por imagem
- Institutos de Investigação do Cancro
- Outros
Com base no utilizador final, o mercado está segmentado em hospitais, laboratórios associados, laboratórios de diagnóstico independentes, centros de diagnóstico por imagem, institutos de investigação do cancro, entre outros.
Canal de Distribuição
- Concurso Direto
- Vendas no Retalho
Com base no canal de distribuição, o mercado está segmentado em concurso direto e vendas a retalho.
Análise/perspetivas regionais do mercado de diagnóstico de leucemia mieloide aguda da Ásia-Pacífico
O mercado de diagnóstico de leucemia mieloide aguda da Ásia-Pacífico é analisado e são fornecidos insights e tendências do tamanho do mercado por país com base no tipo de produto, tipo de teste, tipo de cancro, faixa etária, sexo, utilizador final e canal de distribuição.
Os países abrangidos neste relatório de mercado são a China, o Japão, a Índia, a Austrália, a Coreia do Sul, a Indonésia, as Filipinas, a Tailândia, a Malásia, o Vietname, Singapura e o resto da Ásia-Pacífico, como referido acima.
A China domina o mercado de diagnóstico de leucemia mieloide aguda da Ásia-Pacífico em termos de quota de mercado e receitas e continuará a florescer o seu domínio durante o período de previsão. Isto deve-se aos novos avanços tecnológicos no diagnóstico da leucemia na região, aos crescentes investimentos em I&D e ao lançamento de novos produtos que estão a impulsionar o crescimento do mercado.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações nas regulamentações do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados, como vendas de novos e de reposição, demografia do país, epidemiologia de doenças e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e a disponibilidade das marcas da Ásia-Pacífico e os desafios enfrentados devido à concorrência das marcas locais e nacionais e o impacto dos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país .
Análise do panorama competitivo e da quota de mercado de diagnóstico da leucemia mielóide aguda da Ásia-Pacífico
O panorama competitivo do mercado de diagnóstico de leucemia mieloide aguda da Ásia-Pacífico fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, presença na Ásia-Pacífico, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produto, largura e amplitude do produto, e domínio da aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas em relação ao mercado.
Alguns dos principais players que operam no mercado de diagnóstico de leucemia mieloide aguda da Ásia-Pacífico são a CANON MEDICAL SYSTEMS CORPORATION, a Sysmex Corporation, a F. Hoffmann-La Roche Ltd, a Siemens Healthcare GmbH, a Abbott, a QIAGEN, a Agilent Technologies, Inc, a BIOMÉRIEUX e a Exact Corporação de Ciências, entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS
5.1 REGULATORY SCENARIO IN THE U.S.
5.2 REGULATORY SCENARIO IN AUSTRALIA
5.3 REGULATORY SCENARIO IN JAPAN
5.4 REGULATORY SCENARIO IN CHINA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER
6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS
6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER
6.2 RESTRAINTS
6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS
6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA
6.3 OPPORTUNITIES
6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA
6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
6.4 CHALLENGES
6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 BIOPSY INSTRUMENTS
7.2.1.1 BONE MARROW BIOPSY
7.2.1.2 NEEDLE BIOPSY
7.2.1.3 SURGICAL BIOPSY
7.2.1.4 OTHERS
7.2.2 PATHOLOGY-BASED INSTRUMENTS
7.2.2.1 PCR INSTRUMENTS
7.2.2.2 SLIDE STAINING SYSTEMS
7.2.2.3 TISSUE PROCESSING SYSTEMS
7.2.2.4 CELL PROCESSORS
7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS
7.2.3 IMAGING INSTRUMENTS
7.2.3.1 ULTRASOUND SYSTEMS
7.2.3.2 CT SYSTEMS
7.2.3.3 MRI SYSTEMS
7.2.3.4 OTHERS
7.2.4 OTHERS
7.3 CONSUMABLES & ACCESSORIES
7.3.1 KITS
7.3.1.1 PCR KITS
7.3.1.2 DNA POLYMERASE KITS
7.3.1.3 NUCLEIC ACID ISOLATION KITS
7.3.1.4 OTHERS
7.3.2 REAGENTS
7.3.2.1 ASSAYS
7.3.2.2 BUFFERS
7.3.2.3 PRIMERS
7.3.2.4 OTHERS
7.3.3 PROBES
7.3.4 OTHER CONSUMABLES
8 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 BLOOD TEST
8.2.1 COMPLETE BLOOD COUNT (CBC)
8.2.2 BLOOD CHEMISTRY TESTS
8.2.3 OTHERS
8.3 IMAGING TEST
8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN
8.3.2 MRI
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
8.3.4 OTHERS
8.4 BONE MARROW TESTS
8.4.1 BONE MARROW ASPIRATE
8.4.2 BONE MARROW BIOPSY
8.4.3 OTHERS
8.5 GENETIC TESTS
8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
8.5.2 KARYOTYPING
8.5.3 OTHERS
8.6 BIOMARKER TEST
8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER
8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER
8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER
8.7 IMMUNOPHENOTYPING
8.7.1 FLOW CYTOMETRY
8.7.2 IMMUNOHISTOCHEMISTRY
8.7.3 OTHERS
8.8 OTHERS
9 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE
9.1 OVERVIEW
9.2 MYELOBLASTIC (M0)
9.3 MYELOBLASTIC (M1)
9.4 MYELOBLASTIC (M2)
9.5 PROMYELOCYTIC (M3)
9.6 MYELOMONOCYTIC (M4)
9.7 MONOCYTIC (M5)
9.8 ERYTHROLEUKEMIA (M6)
9.9 MEGAKARYOCYTIC (M7)
10 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 65 AND ABOVE
10.3 30-65
10.4 BELOW 21
10.5 21-29
11 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 ASSOCIATED LABS
12.4 INDEPENDENT DIAGNOSTIC LABORATORIES
12.5 DIAGNOSTIC IMAGING CENTERS
12.6 CANCER RESEARCH INSTITUTES
12.7 OTHERS
13 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION
14.1 ASIA-PACIFIC
14.1.1 CHINA
14.1.2 JAPAN
14.1.3 INDIA
14.1.4 AUSTRALIA
14.1.5 SOUTH KOREA
14.1.6 INDONESIA
14.1.7 PHILIPPINES
14.1.8 THAILAND
14.1.9 MALAYSIA
14.1.10 VIETNAM
14.1.11 SINGAPORE
14.1.12 REST OF ASIA-PACIFIC
15 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 CANON MEDICAL SYSTEMS CORPORATION.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 SYSMEX CORPORATION
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 EPIGENOMICS AG.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 MYRIAD GENETICS, INC..
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F. HOFFMANN- LA ROCHE LTD
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 AGILENT TECHNOLOGIES, INC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BD
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 BIOMERIEUX
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BIO-RAD LABORATORIES, INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 DIASORIN S.P.A.
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 EXACT SCIENCES CORPORATION
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 FONAR CORP.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 HOLOGIC INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 ILLUMINA, INC.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 KONINKLIJKE PHILIPS N.V.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 MEDONICA CO. LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 MERCK KGAA
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 PLEXBIO
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENTS
17.21 QIAGEN
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 QUEST DIAGNOSTICS INCORPORATED
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENTS
17.23 SIEMENS HEALTHCARE GMBH
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 SONIC HEALTHCARE
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
17.25 STERNMED GMBH
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENTS
17.26 THERMO FISHER SCIENTIFIC INC.
17.26.1 COMPANY SNAPSHOT
17.26.2 REVENUE ANALYSIS
17.26.3 PRODUCT PORTFOLIO
17.26.4 RECENT DEVELOPMENT
17.27 TIME MEDICAL HOLDING
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Lista de Tabela
TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA
TABLE 2 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 ASIA PACIFIC INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 ASIA PACIFIC INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 ASIA PACIFIC BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 ASIA PACIFIC PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 ASIA PACIFIC IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 ASIA PACIFIC CONSUMABLES AND ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 ASIA PACIFIC KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 ASIA PACIFIC REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 12 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 ASIA PACIFIC BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 ASIA PACIFIC BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 15 ASIA PACIFIC IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 ASIA PACIFIC IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 17 ASIA PACIFIC BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 ASIA PACIFIC BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 19 ASIA PACIFIC GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 ASIA PACIFIC GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 ASIA PACIFIC BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 ASIA PACIFIC BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 23 ASIA PACIFIC IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 ASIA PACIFIC IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 25 ASIA PACIFIC OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 27 ASIA PACIFIC MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 ASIA PACIFIC MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 ASIA PACIFIC MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 ASIA PACIFIC PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 ASIA PACIFIC MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 ASIA PACIFIC MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 ASIA PACIFIC ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 ASIA PACIFIC MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 36 ASIA PACIFIC 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 ASIA PACIFIC 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 ASIA PACIFIC BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 ASIA PACIFIC 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 41 ASIA PACIFIC MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 ASIA PACIFIC FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 44 ASIA PACIFIC HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 ASIA PACIFIC ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 ASIA PACIFIC INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 ASIA PACIFIC DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 ASIA PACIFIC OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 51 ASIA PACIFIC DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 ASIA PACIFIC RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 54 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 ASIA-PACIFIC INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 ASIA-PACIFIC PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 ASIA-PACIFIC IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 ASIA-PACIFIC BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 59 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 ASIA-PACIFIC KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 ASIA-PACIFIC REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 ASIA-PACIFIC IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 ASIA-PACIFIC BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 65 ASIA-PACIFIC BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 ASIA-PACIFIC BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 ASIA-PACIFIC IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 ASIA-PACIFIC GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 69 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 70 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 71 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 72 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 73 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 74 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 CHINA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 CHINA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 CHINA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 CHINA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 CHINA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 80 CHINA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 CHINA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 82 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 83 CHINA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 CHINA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 CHINA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 86 CHINA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 CHINA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 88 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 89 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 90 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 91 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 93 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 94 JAPAN INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 JAPAN PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 JAPAN IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 JAPAN BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 JAPAN CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 JAPAN KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 JAPAN REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 102 JAPAN IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 103 JAPAN BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 JAPAN BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 JAPAN BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 JAPAN IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 107 JAPAN GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 109 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 110 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 111 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 112 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 113 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 114 INDIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 115 INDIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 116 INDIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 INDIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 INDIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 119 INDIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 INDIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 122 INDIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 123 INDIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 124 INDIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 125 INDIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 126 INDIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 INDIA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 129 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 130 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 131 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 132 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 133 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 134 AUSTRALIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 135 AUSTRALIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 136 AUSTRALIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 137 AUSTRALIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 AUSTRALIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 AUSTRALIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 140 AUSTRALIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 142 AUSTRALIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 143 AUSTRALIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 AUSTRALIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 AUSTRALIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 146 AUSTRALIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 147 AUSTRALIA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 148 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 149 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 150 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 151 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 152 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 153 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 154 SOUTH KOREA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 155 SOUTH KOREA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 156 SOUTH KOREA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 157 SOUTH KOREA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 158 SOUTH KOREA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 159 SOUTH KOREA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 160 SOUTH KOREA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 162 SOUTH KOREA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 163 SOUTH KOREA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 164 SOUTH KOREA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 165 SOUTH KOREA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 166 SOUTH KOREA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 SOUTH KOREA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 168 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 169 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 170 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 171 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 172 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 173 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 174 INDONESIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 175 INDONESIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 176 INDONESIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 177 INDONESIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 178 INDONESIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 179 INDONESIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 180 INDONESIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 181 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 182 INDONESIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 183 INDONESIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 184 INDONESIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 185 INDONESIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 INDONESIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 187 INDONESIA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 188 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 189 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 190 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 191 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 192 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 193 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 194 PHILIPPINES INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 195 PHILIPPINES PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 196 PHILIPPINES IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 197 PHILIPPINES BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 198 PHILIPPINES CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 199 PHILIPPINES KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 200 PHILIPPINES REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 201 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 202 PHILIPPINES IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 203 PHILIPPINES BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 204 PHILIPPINES BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 205 PHILIPPINES BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 206 PHILIPPINES IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 207 PHILIPPINES GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 208 PHILIPPINES GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 209 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 210 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 211 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 212 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 213 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 214 THAILAND INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 215 THAILAND PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 216 THAILAND IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 217 THAILAND BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 218 THAILAND CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 219 THAILAND KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 220 THAILAND REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 221 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 222 THAILAND IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 223 THAILAND BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 THAILAND BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 225 THAILAND BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 226 THAILAND IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 227 THAILAND GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 228 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 229 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 230 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 231 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 232 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 233 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 234 MALAYSIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 235 MALAYSIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 236 MALAYSIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 237 MALAYSIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 238 MALAYSIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 239 MALAYSIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 240 MALAYSIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 241 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 242 MALAYSIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 243 MALAYSIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 244 MALAYSIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 245 MALAYSIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 246 MALAYSIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 247 MALAYSIA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 248 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 249 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 250 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 251 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 252 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 253 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 254 VIETNAM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 255 VIETNAM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 256 VIETNAM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 257 VIETNAM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 258 VIETNAM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 259 VIETNAM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 260 VIETNAM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 261 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 262 VIETNAM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 263 VIETNAM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 264 VIETNAM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 265 VIETNAM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 266 VIETNAM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 267 VIETNAM GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 268 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 269 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 270 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 271 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 272 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 273 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 274 SINGAPORE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 275 SINGAPORE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 276 SINGAPORE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 277 SINGAPORE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 278 SINGAPORE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 279 SINGAPORE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 280 SINGAPORE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 281 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 282 SINGAPORE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 283 SINGAPORE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 284 SINGAPORE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 285 SINGAPORE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 286 SINGAPORE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 287 SINGAPORE GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 288 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 289 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 290 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 291 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 292 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 293 REST OF ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
Lista de Figura
FIGURE 1 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 2 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DROC ANALYSIS
FIGURE 4 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : MARKET END USER COVERAGE GRID
FIGURE 9 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET
FIGURE 14 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES)
FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES)
FIGURE 16 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 17 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 18 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 19 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 20 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 21 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 22 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 23 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 24 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 25 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 26 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 27 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 28 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 29 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 30 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 31 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 32 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2022
FIGURE 33 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)
FIGURE 34 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 35 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 36 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 37 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 38 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 39 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 41 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 42 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 43 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 45 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 46 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 47 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 48 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 49 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
